IMMUNOHISTOCHEMICAL EXPRESSION AND MOLECULAR PROFILING OF PD-L1 AND KI-67 IN TRIPLE-NEGATIVE BREAST CARCINOMA: CORRELATION WITH CLINICOPATHOLOGICAL PARAMETERS
Genetics and Molecular Research · 02.06.2026
DOI: 10.4238/3w949y48 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics and Molecular Research, online erschienen am 02.06.2026. Verfasst von Dr Memoona Kokab und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Background
Triple-negative breast carcinoma (TNBC) is an aggressive subtype of breast cancer lacking targeted hormonal therapies. Biomarkers such as programmed death-ligand 1 (PD-L1) and Ki-67 have gained importance in understanding tumor behavior, immune evasion, and proliferative activity.
Objective
To evaluate the immunohistochemical expression and molecular profiling of PD-L1 and Ki-67 in TNBC and to assess their correlation with clinicopathological parameters.
Methods
This was a cross-sectional analytical study conducted in the Pathology Department ( Histopathology section) of Fauji Foundation Hospital Lahore, from March 2025 to December 2025, including 85 patients diagnosed with triple-negative breast carcinoma (TNBC) to evaluate the immunohistochemical expression and molecular profiling of PD-L1 and Ki-67 and their correlation with clinicopathological parameters.
Results
PD-L1 positivity was observed in 60.0% of patients and was significantly associated with larger tumor size (4.2 ± 1.5 cm vs 3.3 ± 1.2 cm; p=0.008), higher grade tumors (67.9% vs 46.9%; p=0.041), lymph node positivity (69.6% vs 50.0%; p=0.012), and advanced stage disease (72.9% vs 38.2%; p=0.006). High Ki-67 expression was seen in 77.6% of patients and was significantly associated with larger tumor size (4.1 ± 1.4 cm vs 3.0 ± 1.1 cm; p=0.004), higher grade (90.6% vs 56.3%; p=0.009), and lymph node involvement (83.9% vs 47.4%; p=0.047). The combined PD-L1+/high Ki-67 group showed the most aggressive tumor profile, with highest tumor size (4.4 ± 1.5 cm), nodal involvement (81.0%), and advanced stage (73.8%) (p
Zitieren
APA
Kokab, D. M., Akhtar, D. A., Zahid, D. A., Javaid, D. N., Jamil, D. A., & Sajjad, D. A. (2026). IMMUNOHISTOCHEMICAL EXPRESSION AND MOLECULAR PROFILING OF PD-L1 AND KI-67 IN TRIPLE-NEGATIVE BREAST CARCINOMA: CORRELATION WITH CLINICOPATHOLOGICAL PARAMETERS. Genetics and Molecular Research. https://doi.org/10.4238/3w949y48
Vancouver
Kokab DM, Akhtar DA, Zahid DA, Javaid DN, Jamil DA, Sajjad DA. IMMUNOHISTOCHEMICAL EXPRESSION AND MOLECULAR PROFILING OF PD-L1 AND KI-67 IN TRIPLE-NEGATIVE BREAST CARCINOMA: CORRELATION WITH CLINICOPATHOLOGICAL PARAMETERS. Genetics and Molecular Research. 2026. doi:10.4238/3w949y48
BibTeX
@article{Kokab2026,
author = {Kokab, Dr Memoona and Akhtar, Dr Azra and Zahid, Dr Aima and Javaid, Dr Noreen and Jamil, Dr Aisha and Sajjad, Dr Ayesha},
title = {IMMUNOHISTOCHEMICAL EXPRESSION AND MOLECULAR PROFILING OF PD-L1 AND KI-67 IN TRIPLE-NEGATIVE BREAST CARCINOMA: CORRELATION WITH CLINICOPATHOLOGICAL PARAMETERS},
journal = {Genetics and Molecular Research},
year = {2026},
doi = {10.4238/3w949y48}
}
EUVIMED